La La Anthony Partners with Amgen to Raise Awareness on Plaque Psoriasis
Key TakeawaysLa La Anthony opens up about her personal journey with plaque psoriasis and encourages open communication with doctors about treatment needs.
The...
THYROID Eye Disease Treatment with TEPEZZA Receives Approval in Japan
Key TakeawaysTEPEZZA offers a new non-surgical treatment for active TED.
The approval is based on a successful Phase 3 trial with 89% of...
Amgen Wins with Uplizna in Myasthenia Gravis, Rocatinlimab Faces Mixed Reviews
Key TakeawaysAmgen's Uplizna shows strong results in myasthenia gravis, outperforming expectations.
Rocatinlimab improves symptoms in eczema but meets only modest analyst expectations.
Uplizna's...
Psoriasis, particularly moderate to severe plaque psoriasis, presents significant challenges for children and adolescents, affecting both their physical health and quality of life. Amgen...
Obesity Drug Development: Amgen Discusses Differentiation of MariTide Amid Competitive Landscape
Obesity has become a central focus for pharmaceutical innovation, and Amgen is positioning itself as a key player in this arena with its obesity...
Leukemia Treatment Advances with FDA Approval of Blincyto by Amgen for B-ALL
Leukemia treatment has advanced with the Food and Drug Administration's (FDA) approval of Amgen’s Blincyto (blinatumomab) for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic...
FDA Approves Amgen’s IMDELLTRA™ for Lung Cancer, Offering New Hope for Patients
Amgen's groundbreaking IMDELLTRA™ (tarlatamab-dlle) therapy has received the Food and Drug Administration (FDA) approval for the treatment of extensive-stage small cell lung cancer (ES-SCLC)...
Competition Heats Up for First-Line KRAS Inhibitor in Lung Cancer Treatment
In the relentless quest to combat KRAS-mutated non-small cell lung cancer (NSCLC), Amgen's Lumakras and Mirati's Krazati have secured approval for second-line treatment. However,...
